INmune Bio (NASDAQ:INMB) Upgraded at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of INmune Bio (NASDAQ:INMB) to a strong-buy rating in a research note published on Tuesday morning,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Alliance Global Partners started coverage on shares of INmune Bio in a research report on Monday, October 21st. They set a “buy” rating and a $20.00 price objective on the stock. Rodman & Renshaw initiated coverage on INmune Bio in a research report on Tuesday. They set a “buy” rating and a $23.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.75.

INmune Bio Stock Up 1.8 %

Shares of NASDAQ:INMB opened at $9.22 on Tuesday. The company’s 50-day moving average price is $5.62 and its 200 day moving average price is $6.08. The company has a market cap of $204.43 million, a PE ratio of -4.23 and a beta of 1.78. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, October 31st. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same period in the previous year, the company earned ($0.48) earnings per share. As a group, equities analysts anticipate that INmune Bio will post -2.24 EPS for the current year.

Hedge Funds Weigh In On INmune Bio

Hedge funds have recently bought and sold shares of the business. Praetorian PR LLC raised its stake in shares of INmune Bio by 61.0% in the 3rd quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after acquiring an additional 295,800 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of INmune Bio by 332.1% in the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after buying an additional 89,091 shares during the last quarter. State Street Corp boosted its holdings in shares of INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after buying an additional 58,838 shares during the period. XTX Topco Ltd acquired a new position in INmune Bio in the 3rd quarter valued at $249,000. Finally, Westside Investment Management Inc. raised its holdings in INmune Bio by 57.3% in the 3rd quarter. Westside Investment Management Inc. now owns 71,315 shares of the company’s stock worth $384,000 after acquiring an additional 25,975 shares during the period. 12.72% of the stock is owned by institutional investors and hedge funds.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.